Sahajanand Medical Technologies Gets Credit Rating Upgrade

CRISIL A-/Stable for long-term bank loans; CRISIL A2+ for short-term facilities.

Reader Takeaway: Higher ratings signal improved creditworthiness, though investors should monitor NPPA price caps and working capital cycles.

What just happened

CRISIL Ratings has upgraded the bank loan facilities for Sahajanand Medical Technologies Limited (SMTL) and its subsidiary, SMT Cardiovascular Private Limited. The primary long-term rating for SMTL moved to CRISIL A-/Stable from BBB+/Stable, while the short-term rating was elevated to A2+. These revisions follow the company’s recent IPO completion in October 2026.

Why this matters

A rating upgrade typically indicates an improved ability to service debt and stronger overall financial health. For investors, this suggests that SMTL has solidified its market position in the Indian coronary stent (DES) segment and possesses the liquidity to manage its operations more effectively as it scales.

The backstory

The group demonstrated solid performance, with operating revenue rising to Rs 1,214 crore in fiscal 2026, up from Rs 1,032 crore in fiscal 2025. Operating margins have held steady at 13.14% over the past three years. This growth, paired with a cleaner balance sheet post-IPO, supported the credit profile revision.

Risks to watch

Despite the positive outlook, the company faces inherent challenges. These include exposure to NPPA regulatory pricing caps on medical devices, sensitivity to foreign exchange fluctuations, and raw material price volatility. Additionally, the business requires significant working capital, leading to consistently high gross current assets.

What to track next

Investors should focus on whether the group can sustain its current growth momentum and margin levels. Continued management of the working capital cycle remains essential for preserving the stable outlook assigned by the rating agency.